TNFRSF12A and Alzheimer disease: Additionally, sFn14 may help to develop substrate‐preferring GSIs which preferentially block generation of the Aβ peptide in AD over the cleavage of other substrates, such as Fn14, and, thus, avoid the side effects observed upon chronic GSI treatment.